IMUNON (NASDAQ: IMNN) has announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy (N/ACT) showing continued improvement in median overall survival (OS) in women with newly diagnosed advanced ovarian cancer.
The increase in median OS among women treated with IMNN-001 in the trial rose from the previously reported 11.1 months to 14.7 months following final data analysis.
In a statement, Premal H. Thaker, MD, chief of gynecologic oncology, David & Lynn Mutch distinguished professor of obstetrics & gynecology, director of gynecologic oncology clinical research at Washington University School of Medicine, OVATION 2 study chair and study chair of Phase 3 OVATION 3 trial, commented, “It is very encouraging to see results from the OVATION 2 trial indicating that treatment with IMNN-001 was associated with an overall survival benefit of more than a year in patients treated with IMNN-001 plus chemotherapy and more than two years in women also receiving PARP inhibitors as part of maintenance therapy. These new findings are especially exciting given that there have been no meaningful advances in standard of care in ovarian cancer in the last 30 years. Importantly, with these new efficacy results, IMNN-001 continues to maintain a highly favorable safety and tolerability profile, further reinforcing the potential of this IL-12 immunotherapy to represent a landmark advance in treatment for women who are in desperate need of new and improved treatment options.”
